SPRAY-DRIED CHITOSAN MICROSPHERES FOR SUSTAINED DELIVERY OF TRIFLUOPERAZINE HYDROCHLORIDE: FORMULATION AND IN VITRO EVALUATION

ANJU PARAMBIL; SABA MAANVIZHI; ARUL KUTTALINGAM; VELLAPANDIAN CHITRA

doi:10.22159/ijap.2023v15i3.47222

Authors

ANJU PARAMBIL College of Pharmaceutical Sciences, Government Medical College, Kozhikode 673008, Kerala, India https://orcid.org/0000-0001-9720-9393
SABA MAANVIZHI Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research(DU), Porur, Chennai 600116, Tamil Nadu, India https://orcid.org/0000-0002-3325-2162
ARUL KUTTALINGAM College of Pharmaceutical Sciences, Government Medical College, Thiruvananthapuram 695011, Kerala, India
VELLAPANDIAN CHITRA SRM College of Pharmacy, SRMIST, Kattankulathur 603203. Tamilnadu, India

DOI:

https://doi.org/10.22159/ijap.2023v15i3.47222

Keywords:

Trifluoperazine hydrochloride, Method Validation, Microparticles

Abstract

Objective: Sustained release systems have the potential to enhance the therapeutic responses in the long-term management of psychiatric disorders. In the present study, cross-linked microspheres of the antipsychotic drug Trifluoperazine (TFP) were prepared using biodegradable polymer-chitosan and various in vitro evaluations were performed on the prepared microspheres.

Methods: The spray drying technique was used to prepare TFP-loaded chitosan microspheres. Tripolyphosphate (TPP) was incorporated into the chitosan solutions as a cross-linking agent in varying concentrations. Different evaluations like production yield, encapsulation efficiency, drug-polymer compatibility, Scanning Electron Microscopy (SEM), X-ray diffraction studies (XRD), Differential Scanning Colorimetry (DSC), particle size, zeta potential analysis and in vitro drug release studies were performed on the developed formulations.

Results: The formulated microparticles exhibited production yields ranging from 38.51 to 57.21% and had reasonably good encapsulation efficiencies (54.52-78.35%). The drug excipient compatibility was confirmed by Infrared Spectroscopy. All the microspheres showed positive zeta potential with a mean diameter ranging from 1.45-3.61µ. SEM images revealed the formation of spherical particles with indentations on the surface. XRD and DSC studies confirmed the presence of an amorphous form of the drug inside the microspheres. The in vitro release profile of TFP from cross-linked chitosan microspheres was influenced considerably by changing the concentration of polymer and crosslinking agent in the formulation. The drug release from (0.5%) chitosan microspheres reduced from 91% to 79%, when TPP concentration was increased from 10% w/w to 30% w/w. All the formulations clearly showed a burst release of the drug in the initial hours and a subsequent sustained release profile.

Conclusion: The results of this study suggest that TPP crosslinked spray-dried chitosan microparticles could be a promising method for developing a long-acting drug delivery system intended to effectively treat schizophrenia.

Downloads

Download data is not yet available.

References

Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. P T. 2014;39(9):638-45. PMID 25210417.

Marques LO, Lima MS, Soares BG. Trifluoperazine for schizophrenia. Cochrane Database Syst Rev. 2004;2004(1):CD003545. doi: 10.1002/14651858.CD003545.pub2, PMID 14974020.

Keith S. Advances in psychotropic formulations. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6):996-1008. doi: 10.1016/j.pnpbp.2006.03.031, PMID 16678954.

Siegel SJ. Extended release drug delivery strategies in psychiatry: theory to practice. Psychiatry (Edgmont). 2005 Jun 1;2(6):22-31. PMID 21152152.

Krishnaraj K, Chandrasekar MJN, Nanjan MJ, Muralidharan S, Manikandan D. Development of sustained release antipsychotic tablets using novel polysaccharide isolated from Delonix regia seeds and its pharmacokinetic studies. Saudi Pharm J. 2012;20(3):239-48. doi: 10.1016/j.jsps.2011.12.003, PMID 24115903.

Akila RM, Maria Shaji D. Ginger loaded chitosan nanoparticles for the management of 3–nitropropionic acid-induced Huntington’s disease-like symptoms in male wistar rats. Int J Pharm Pharm Sci. 2022;14:28-36. doi: 10.22159/ijpps.2022v14i1.42894.

El-Assal MI, Samuel D. Optimization of rivastigmine chitosan nanoparticles for neurodegenerative Alzheimer; in vitro and ex vivo characterizations. Int J Pharm Pharm Sci. 2022;14:17-27. doi: 10.22159/ijpps.2022v14i1.43145.

Cheung RC, Ng TB, Wong JH, Chan WY. Chitosan: an update on potential biomedical and pharmaceutical applications. Mar Drugs. 2015;13(8):5156-86. doi: 10.3390/md13085156, PMID 26287217.

Mitra A, Dey B. Chitosan microspheres in novel drug delivery systems. Indian J Pharm Sci. 2011;73(4):355-66. doi: 10.4103/0250-474X.95607, PMID 22707817.

Krishnakumar A, Srivastava R. In vitro in vivo studies on floating microspheres for gastroretentive drug delivery system: a review. Asian J Pharm Clin Res. 2021;14:13-26.

Zhang ZL, Li LJ, Sun D, Wang M, Shi JR, Yang D. Preparation and properties of chitosan‐based microspheres by spray drying. Food Sci Nutr. 2020;8(4):1933-41. doi: 10.1002/fsn3.1479, PMID 32328259.

Zhou J, Chen Y, Luo M, Deng F, Lin S, Wu W. Dual cross-linked chitosan microspheres formulated with spray-drying technique for the sustained release of levofloxacin. Drug Dev Ind Pharm. 2019;45(4):568-76. doi: 10.1080/03639045.2019.1569025, PMID 30652515.

Desai KGH, Park HJ. Preparation of cross-linked chitosan microspheres by spray drying: effect of cross-linking agent on the properties of spray dried microspheres. J Microencapsul. 2005;22(4):377-95. doi: 10.1080/02652040500100139, PMID 16214786.

Wei Y, Huang YH, Cheng KC, Song YL. Investigations of the influences of processing conditions on the properties of spray dried chitosan-tripolyphosphate particles loaded with theophylline. Sci Rep. 2020;10(1):1155. doi: 10.1038/s41598-020-58184-3, PMID 31980705.

Pathak S, Vyas SP, Pandey A. Development, characterization and in vitro release kinetic studies of ibandronate loaded chitosan nanoparticles for effective management of osteoporosis. Int J App Pharm. 2021;13:120-5. doi: 10.22159/ijap.2021v13i6.42697.

Zeng W, Hui H, Liu Z, Chang Z, Wang M, He B. TPP ionically cross-linked chitosan/PLGA microspheres for the delivery of NGF for peripheral nerve system repair. Carbohydr Polym. 2021;258:117684. doi: 10.1016/j.carbpol.2021.117684, PMID 33593557.

Gharsallaoui A, Roudaut G, Chambin O, Voilley A, Saurel R. Applications of spray-drying in microencapsulation of food ingredients: an overview. Food Res Int. 2007;40(9):1107-21. doi: 10.1016/j.foodres.2007.07.004.

Ping H, Davis SS, Illum L. Chitosan microspheres prepared by spray dying method. Eur J Pharm Sci. 1996;4:S173.

Ganna S, Kotakadi SM, Mohammed RA, Shaik MI, Nannepaga JS. Optimization and characterization of rivastigmine-loaded nanostructured lipid carriers. Int J Curr Pharm Sci. 2021;13:46-51. doi: 10.22159/ijcpr.2021v13i3.42093.

Fischetti T, Celikkin N, Contessi Negrini N, Fare S, Swieszkowski W. Tripolyphosphate-crosslinked chitosan/gelatin biocomposite ink for 3D printing of uniaxial scaffolds. Front Bioeng Biotechnol. 2020;8:400. doi: 10.3389/fbioe.2020.00400, PMID 32426350.

Potas J, Szymanska E, Winnicka K. Challenges in developing of chitosan–based polyelectrolyte complexes as a platform for mucosal and skin drug delivery. Eur Polym J. 2020;140:110020. doi: 10.1016/j.eurpolymj.2020.110020.

Batista P, Castro P, Madureira AR, Sarmento B, Pintado M. Development and characterization of chitosan microparticles-in-films for buccal delivery of bioactive peptides. Pharmaceuticals (Basel). 2019;12(1):1-15. doi: 10.3390/ph12010032, PMID 30791572.

Aranaz I, Panos I, Peniche C, Heras A, Acosta N. Chitosan spray-dried microparticles for controlled delivery of venlafaxine hydrochloride. Molecules. 2017;22(11):1-13. doi: 10.3390/molecules22111980, PMID 29140306.

Wang S, Sun Y, Zhang J, Cui X, Xu Z, Ding D. Astragalus polysaccharides/chitosan microspheres for nasal delivery: preparation, optimization, characterization, and pharmacodynamics. Front Pharmacol. 2020;11:230. doi: 10.3389/fphar.2020.00230, PMID 32256349.

Moffat AC, Osselton MD, Widdop B, Watts J. Clarke’s analysis of drugs and poisons. London: Pharmaceutical press; 2011.

Rajesh P, Gunasekaran S, Gnanasambandan T, Seshadri S. Molecular structure and vibrational analysis of trifluoperazine by FT-IR, FT-Raman and UV-vis spectroscopies combined with DFT calculations. Spectrochim Acta A Mol Biomol Spectrosc. 2015;137:1184-93. doi: 10.1016/j.saa.2014.08.100, PMID 25305610.

Queiroz MF, Melo KRT, Sabry DA, Sassaki GL, Rocha HAO. Does the use of chitosan contribute to oxalate kidney stone formation? Mar Drugs. 2015;13:141-58.

Ogunjimi AT, Fiegel J, Brogden NK. Design and characterization of spray-dried chitosan-naltrexone microspheres for microneedle-assisted transdermal delivery. Pharmaceutics. 2020;12(6):496. doi: 10.3390/pharmaceutics12060496, PMID 32485999.

Post A, Warren RJ, Zarembo JE. Trifluoperazine hydrochloride. Anal Profiles Drug Subst Excipients. 1981;9(C):543-81.

Hazra M, Dasgupta Mandal D, Mandal T, Bhuniya S, Ghosh M. Designing polymeric microparticulate drug delivery system for hydrophobic drug quercetin. Saudi Pharm J. 2015;23(4):429-36. doi: 10.1016/j.jsps.2015.01.007, PMID 27134546.

Bartos C, Varga P, Szabo Revesz P, Ambrus R. Physico-chemical and in vitro characterization of chitosan-based microspheres intended for nasal administration. Pharmaceutics. 2021;13(5):1-13. doi: 10.3390/pharmaceutics13050608, PMID 33922172.

British Pharmacopoeia. Commission. Vol. II. British Pharmacopoeia. London: TSO; 2016.

Patel KS, Patel MB. Preparation and evaluation of chitosan microspheres containing nicorandil. Int J Pharm Investig. 2014;4(1):32-7. doi: 10.4103/2230-973X.127738, PMID 24678460.